Register: GORD Management Today: Optimising the use of PPIs and alginates in clinical practice

Home
Agenda

1Register
2About you
3Your data
4Confirmation

GORD Management Today: Optimising the use of PPIs and alginates in clinical practice

Tuesday, October 6, 2026, 12:00 PM - 1:00 PM

Registration

This promotional webinar has been organised and funded by Reckitt Benckiser and is intended for UK healthcare professionals only.

Please complete all the fields on the registration form. Should you have any questions about the event, you can visit the FAQs page or email events@cogora.com who are responsible for the logistics of these meetings.

Are you a ‘health professional’ (This includes members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine)?

Yes

No

Which of the following best describes your job title?

GP

Hospital Doctor

Nurse

Pharmacist

Other

Email Address

Registrant Type

Sorry, but under UK and EU regulations we are only permitted to allow health professionals to access this site and register for this event. If you believe you are eligible but have answered No to the question above, please email events@cogora.com

Already Registered? View or modify your existing registration

Summary of Product Characteristics (SmPC)

Essential Information Gaviscon Advance Aniseed Flavour Oral Suspension PL 00063/0749

Active substances: Each 10 ml dose contains sodium alginate 1000 mg and potassium hydrogen carbonate 200 mg.

Indications: Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy

Dosage and administration:

Adults and children 12 years and over: 5-10ml after meals and at bedtime.
Children under 12 years: Should be given only on medical advice.
Elderly: No dose modification is required for this age group.
Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary.

Contraindications: This medicinal product is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients, or any of the excipients listed in section 6.1, including methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216).

Special warnings and precautions for use:

If symptoms do not improve after 7 days, the clinical situation should be reviewed.
This medicinal product contains 57.85 mg sodium per 5 ml, equivalent to 2.9 % of the WHO recommended maximum daily intake for sodium. The maximum daily dose of this product is equivalent to 23.14 % of the WHO recommended maximum daily intake for sodium.
This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
Potassium: This medicine contains 1.0 mmol (39.06 mg) potassium per 5 ml . To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.
Each 10 ml contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216): May cause allergic reactions (possibly delayed).

This medicine contains 0.525 mg benzyl alcohol in each 5 ml.
Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).
Ask your doctor or pharmacist for advice if you have liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).

Fertility, pregnancy and lactation:

Pregnancy: Clinical studies in more than 500 pregnant women as well as a large amount of data from post-marketing experience indicate no malformative nor foeto/neonatal toxicity of the active substances. Gaviscon can be used during pregnancy, if clinically needed.
Breast feeding: No known effect on breast fed infants. Gaviscon can be used during breast feeding.
Fertility: No known effect on human fertility.

Side effects: Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

System Organ Class	Frequency	Adverse Event
Gastrointestinal Disorders	Uncommon	Diarrhoea, nausea, vomiting.
Immune System Disorders	Very rare	Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria.
Respiratory, Thoracic and Mediastinal Disorders	Very rare	Respiratory effects such as bronchospasm.

Legal Classification:   GSL.
Licence Holder:   Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS, United Kingdom
Licence Number:   PL 00063/0749
Price:   £XXX 150ml and 500ml
Last Revised:   13-09-2024

Essential Information for Gaviscon Advance Mint Chewable Tablets PL 00063/0613

Active substances: Each tablet contains sodium alginate 500 mg and potassium bicarbonate 100 mg.

Indications: Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. It can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.

Dosage and Administration: For oral administration, after being thoroughly chewed.

Adults and children 12 years and over: One to two tablets after meals and at bedtime.
Children under 12 years: Should be given only on medical advice.
Elderly: No dose modifications necessary for this age group.
Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is necessary

Contraindications: patients with known or suspected hypersensitivity to the active substances or to any of the excipients.

Special warnings and precautions for use:

If symptoms do not improve after 7 days, the clinical situation should be reviewed.

This medicinal product contains 53.22 mg sodium per tablet, equivalent to 2.7% of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 21.28 % of the WHO recommended maximum daily intake for sodium.
This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet (e.g. in some cases of congestive heart failure and renal impairment).
Potassium: This medicine contains potassium 1.01 mmol (39.43 mg) per tablet. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.
Each two-tablet dose contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
This medicine contains 4.5 mg aspartame (E 951) in each tablet. Aspartame (E 951) is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
May cause central nervous system depression in the presence of renal insufficiency and should not be used in patients with renal failure.

Fertility, pregnancy and lactation:

Pregnancy: Clinical studies in more than 500 pregnant women as well as a large amount of data from post-marketing experience indicate no malformative nor foeto/neonatal toxicity of the active substances. Gaviscon can be used during pregnancy, if clinically needed.
Breast feeding: No known effect on breast fed infants. Gaviscon can be used during breast feeding.
Fertility: No known effect on human fertility.

Side effects: Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

System Organ Class	Frequency	Adverse Event
Gastrointestinal Disorders	Uncommon	Diarrhoea, nausea, vomiting.
Immune System Disorders	Very rare	Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria.
Respiratory, Thoracic and Mediastinal Disorders	Very rare	Respiratory effects such as bronchospasm.

Legal Classification:   GSL.
Licence Holder:   Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull, HU8 7DS, United Kingdom.
Licence Number:   PL 00063/0613.
Price:   £XX 24’s.
Last Revised:   13-09-2024

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Reckitt Benckiser by calling 0333 2005 345.

This promotional webinar has been organised and funded by Reckitt Benckiser and is intended for UK healthcare professionals only.

RT-M-P2CZXo July 2026

Privacy Policy
Terms & Conditions

© 2026 Cogora Ltd, 1 Giltspur Street, London EC1A 9DD. Registered in the United Kingdom. Reg. No. 2147432.